DNB Asset Management AS Grows Position in Disc Medicine, Inc. $IRON

DNB Asset Management AS lifted its holdings in shares of Disc Medicine, Inc. (NASDAQ:IRON) by 1,425.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 84,255 shares of the company’s stock after buying an additional 78,733 shares during the period. DNB Asset Management AS’s holdings in Disc Medicine were worth $6,691,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Arizona State Retirement System boosted its position in Disc Medicine by 1.8% in the third quarter. Arizona State Retirement System now owns 6,654 shares of the company’s stock worth $440,000 after purchasing an additional 120 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its position in Disc Medicine by 2.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 7,094 shares of the company’s stock worth $469,000 after purchasing an additional 138 shares during the last quarter. Avanza Fonder AB boosted its position in Disc Medicine by 14.1% in the fourth quarter. Avanza Fonder AB now owns 1,903 shares of the company’s stock worth $151,000 after purchasing an additional 235 shares during the last quarter. Alliancebernstein L.P. boosted its position in Disc Medicine by 1.7% in the third quarter. Alliancebernstein L.P. now owns 24,540 shares of the company’s stock worth $1,622,000 after purchasing an additional 400 shares during the last quarter. Finally, ANTIPODES PARTNERS Ltd purchased a new position in Disc Medicine in the fourth quarter worth about $33,000. 83.70% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the company. Stifel Nicolaus dropped their target price on Disc Medicine from $125.00 to $110.00 and set a “buy” rating on the stock in a research report on Tuesday, February 17th. Wall Street Zen raised Disc Medicine from a “strong sell” rating to a “sell” rating in a research report on Saturday, April 25th. Weiss Ratings reissued a “sell (d-)” rating on shares of Disc Medicine in a research report on Monday, April 20th. Wells Fargo & Company raised their target price on Disc Medicine from $78.00 to $79.00 and gave the stock an “overweight” rating in a research report on Monday, March 2nd. Finally, Cantor Fitzgerald dropped their target price on Disc Medicine from $153.00 to $125.00 and set an “overweight” rating on the stock in a research report on Tuesday, February 17th. Ten investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $105.30.

Insider Activity

In other news, insider William Jacob Savage sold 7,378 shares of the firm’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $65.88, for a total value of $486,062.64. Following the transaction, the insider owned 85,211 shares of the company’s stock, valued at $5,613,700.68. This trade represents a 7.97% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Jean M. Franchi sold 7,081 shares of the firm’s stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $65.47, for a total value of $463,593.07. Following the completion of the transaction, the chief financial officer directly owned 71,343 shares in the company, valued at $4,670,826.21. This trade represents a 9.03% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 27,200 shares of company stock worth $1,815,292 in the last ninety days. Corporate insiders own 3.76% of the company’s stock.

Disc Medicine Stock Down 0.0%

NASDAQ IRON opened at $66.85 on Tuesday. The stock’s 50-day moving average price is $65.55 and its 200-day moving average price is $75.03. The company has a quick ratio of 24.00, a current ratio of 24.00 and a debt-to-equity ratio of 0.04. Disc Medicine, Inc. has a 52 week low of $40.00 and a 52 week high of $99.50. The company has a market capitalization of $2.55 billion, a P/E ratio of -10.10 and a beta of 0.93.

Disc Medicine (NASDAQ:IRON) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($1.65) EPS for the quarter, missing the consensus estimate of ($1.62) by ($0.03). On average, equities research analysts predict that Disc Medicine, Inc. will post -6.78 earnings per share for the current year.

About Disc Medicine

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.